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ABSTRACT 
The intense conditions generated in the core of a collapsing bubble have been the subject of 
intense scrutiny from fields as diverse as marine biology and nuclear fusion. In particular, the 
phenomenon of sonoluminescence - whereby a collapsing bubble emits light - has received 
significant attention. Sonoluminescence has been associated predominantly with millimetre 
sized bubbles excited at low frequencies and under conditions far removed from those 
associated with the use of ultrasound in medicine. In this study, however, we demonstrate that 
sonoluminescence is produced under medically relevant exposure conditions by microbubbles 
commonly used as contrast agents for ultrasound imaging. This provides a mechanistic 
explanation for the somewhat controversial reports of “sonodynamic” therapy (SDT), in which 
light sensitive drugs have been shown to be activated by ultrasound induced cavitation. To 
illustrate this, we demonstrate activation of a photodynamic therapy agent using microbubbles 
and ultrasound. Since ultrasound can be accurately focused at large tissue depths, this opens up 
the potential for generating light at locations that cannot be reached by external sources. This 
could be exploited both for diagnostic and therapeutic applications significantly increasing the 
range of applications that are currently restricted by the limited penetration of light in tissue.  
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INTRODUCTION 
Multi-bubble sonoluminescence is an intense thermal process whereby transient species 
formed during the collapse of bubbles under ultrasound excitation (cavitation) emit light 1. The 
majority of previous studies on sonoluminescence have employed ultrasound frequencies and 
intensities that are significantly different from those used in diagnostic or therapeutic 
ultrasound 2–7. However, with the increasing use of microbubbles in both ultrasound imaging 
and therapy 8, and studies showing sonoluminescence at ultrasound frequencies in the MHz 
range 9–15, there is a need to understand whether these extreme events can in fact occur in tissue. 
In particular, sonoluminescence and the reactive oxygen species associated with violent bubble 
collapse have been suggested as the means by which certain classes of drug can be activated 
by ultrasound 16–20, so called Sonodynamic Therapy (SDT). Reports on SDT have demonstrated 
promising results for the treatment of aggressive and resistant tumour cell lines 21–23. This 
approach relies on the combination of ultrasound, ground state molecular oxygen, and a 
“sensitizer” drug to produce cytotoxic reactive oxygen species in a targeted manner. Thus, SDT 
uses a similar approach to photodynamic therapy (PDT), a modality clinically approved for the 
treatment of superficial lesions and lesions that can be reached with an endoscope24. Ultrasound 
can, however, be more tightly focused in deeper regions of human tissues compared to light, 
allowing SDT potentially to treat a wider range of lesions, more deeply seated in the body 
compared to photodynamic therapy. 
The initial findings of drug activation using ultrasound were reported in 1989 17  and since then, 
a range of sensitisers have been investigated 22,23. Over the last decade, microbubbles have been 
shown to enhance SDT and a correlation between SDT and cavitation has been established, but 
the underlying mechanisms responsible for sensitiser activation have remained uncertain. 
Several theories have been proposed, including sonoluminescence 14,15 and pyrolysis 25 but a 
consensus has yet to be drawn. The aim of this study was to investigate whether 
sonoluminescence events occur during the excitation of phospholipid-coated microbubbles 
using ultrasound parameters previously shown to have a therapeutic effect in vivo 26–29; and 
whether these events could activate a known SDT sensitizer (Rose Bengal). Investigation was 
also made of the production of different types of reactive oxygen species to determine whether 
their formation could provide an alternative or complementary pathway for sensitizer activation 
via pyrolysis (please see Supporting Information). 
EXPERIMENTAL SECTION 
Microbubbles 
1,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC) was obtained from Avanti Polar Lipids 
Inc. (Alabaster, Alabama, USA). N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine, 1,3-diphenylisobenzofuran (DPBF), triethylammonium 
salt (NBD-PE) and singlet oxygen sensor green (SOSG) were purchased from Thermo Fisher 
Scientific. Rose Bengal, Polyoxyethylene (40) stearate (PEG 40S), chloroform and ethanol 
were all obtained from Sigma Aldrich Ltd. (Gillingham, Dorset, UK). Sulphur hexafluoride 
(SF6) and oxygen (O2) gases was purchased from The BOC Group (Guilford, Surrey, UK). 
SonoVue® was purchased from Bracco Research (Geneva, Switzerland). 
 
To produce the microbubbles, a mixture of DBPC and PEG40Ss dissolved in chloroform were 
added to a glass vial to produce a 5-mL batch of microbubbles at a total concentration 4 mg/mL. 
The sample was covered with pierced parafilm and set on a hot plate at 50°C for 12 hours to 
evaporate the chloroform. Once all the solvent evaporated, the dried lipid film was suspended 
in 5 mL of filtered deionised water for 1 hour at 80°C under constant magnetic stirring. The 
magnetic stir bar was then removed.  
 
The lipid mix solution was sonicated at low intensity (QSonica Q125, 20kHz, 3 mm probe tip, 
amplitude: 20%, 1 min) with the sonicator probe tip immersed in the solution. The sonicator 
probe tip was moved to touch the air and water interface and a light flow of sulphur 
hexafluoride (SF6) gas was added to fill the headspace of the sample vial. The sonicator was 
then turned on at high intensity (amplitude: 80%, 20 sec). The samples were capped and cooled 
on ice for 10 mins after which a layer of foam was visible at the top of the sample and a thick 
layer of densely packed microbubbles underneath the foam. To produce O2 filled 
microbubbles, 1-mL samples of SF6 MBs was sparged with oxygen for 2 mins as described in 
30. SonoVue® was prepared according to the manufacturer’s instructions. 
 
Microbubble size and concentration were determined through an analysis of optical images as 
previous studies have confirmed the reliability of this method compared to particle sizing 
devices 31. For this, the microbubble suspension was diluted 1:20 in PBS and 10 μL were loaded 
onto a haemocytometer with a cover slide. 30 microscope images were acquired through an 
optical microscope (Leica DM500 optical microscope, Larch House, Milton Keynes, MK14 
6FG, UK) with a 40x objective lens at room temperature. The images were then analysed using 
purpose written MATLAB code (R2016b, The MathWorks, Natick, MA, USA) to determine 
microbubble mean size and concentration. For all experiments microbubbles with a modal 
diameter of 2.1 ± 1.6 μm (Figure S1) were used, corresponding to the agents used in ultrasound 
imaging and therapy. These were also diluted to 5x105 microbubble/mL in deionised water to 
reflect the concentrations that would be present in the human blood stream following injection. 
 
Exposure Chamber 
A chamber was designed and built for the characterisation of sonoluminescence events to 
enable simultaneous measurements of photon and acoustic emissions from ultrasound excited 
microbubbles. This consisted of a cube, made of black Delrin® to minimise external light 
contamination, with an internal volume of 100 ml (Figure S1). The base of the chamber was 
coated with ultrasound absorbing material (F28, Precision Acoustics, Dorset, UK) to avoid the 
formation of standing waves. Ports in the walls enabled co-alignment of the foci of two optical 
lenses (ACL25416U-A, Ø = 2.54 cm, f = 16 mm, NA = 0.79, ThorLabs, Ely, UK) and two 
ultrasound transducers at the centre of the chamber. Photons were detected using two 
photomultiplier tubes (PMTs, Hamamatsu H10493-03, Welwyn Garden City, UK) coupled to 
the lenses. The first ultrasound transducer (1 MHz centre frequency, 16 mm element diameter 
with an integrated drive system, Sonidel SP100, Dublin, Ireland) was used to transmit 
ultrasound in order to excite the microbubbles. The second transducer (7.5 MHz centre 
frequency unfocused, element diameter 1.25 cm, Olympus V320, Southend on Sea, UK) was 
used to passively receive nonlinear acoustic emissions indicative of cavitation activity. A 
schematic of the set up and associated instrumentation is shown in Figure 1.  
 
 Figure 1. Schematic of the experimental setup used for the simultaneous recording of optical 
and acoustic emissions.  
 
Experimental Protocol 
Sonoluminescence events were investigated in aqueous solutions ± MB, ± Rose Bengal. 
Samples were prepared in filtered deionised water to obtain 5x105 MB / mL as above and 2.5 
μM RB. Samples were injected into the chamber via the filling port and exposed to ultrasound  
for 2 mins (1 MHz centre frequency, 3.5 W/cm2 temporal peak average intensity, 30% duty 
cycle, 100 Hz pulse repetition frequency) during which period 1000 PMT acquisitions were 
recorded. The first PMT was used to measure the overall light emissions. The second was used 
with appropriate filters to measure sonoluminescence at specific wavelengths. The 
corresponding acoustic emissions were recorded using the 7.5 MHz centre frequency 
transducer. A 2 MHz high-pass filter was used to remove the drive frequency from the recorded 
PCD traces before preamplifying (SR445A, SRS, Sunnyvale, CA, USA), digitising it 
(Handyscope HS3, TiePie Engineering, Sneek, Netherlands) and saving it on a computer drive 
for analysis. The effect of bulk temperature was examined to determine if sonoluminescence 
could occur at biologically-relevant temperatures. For this, experiments were conducted with 
a sample temperature of 10, 23, and 37°C, monitored using a PCE-T390 digital thermometer 
from PCE Instruments, before and after ultrasound exposure. 
 
Detection of reactive oxygen species 
The detection of singlet oxygen specifically was accomplished using the commercial product: 
singlet oxygen sensor green (SOSG) which reacts with 1O2 to form SOSG-endoperoxides with 
a strong fluorescence emission around 525-536 nm. The less specific detection of both 1O2 
and / or O2· - was determined through a decrease in absorbance of 1,3-diphenylisobenzofuran 
(DPBF) at 410 nm as it oxidises in the presence of either species forming non-fluorescent 1,2-
phenylenebis(phenylmethanone). For the detection of hydroxyl radical, non-fluorescent 
benzoic acid was used as it becomes permanently fluorescent (Ex: 305 nm / Em: 420 nm) upon 
aromatic hydroxylation by ·OH. 
 
Fluorescence and absorbance measurements were done in quadruplets on COSTAR or 
Greigner UV-Star clear flat-bottom 96-well plates from Sigma-Aldrich (Dorset, UK), using a 
FLUOstar Omega multi-purpose plate reader from BMG Labtech (Aylesbury, Bucks, UK) at 
room temperature. For some of the examination, these measurements were taken before and 
after sample exposition to determine a percent change in the intensity relative to the pre- 
exposure intensity. Sample absorbance measurements were all normalised to that of a blank 
control. 
 
Data analysis 
The acquired acoustic emission traces were fitted with a Tukey window to avoid discontinuities 
and then analysed with a Fast Fourier Transform (FFT) using MATLAB (R2017b The 
Mathworks, Natick, MA, USA). The harmonics (multiples of the drive frequency ± 100 kHz, 
> 2 MHz), ultraharmonics (half-integer harmonics of the drive frequency ± 50 kHz, > 2 MHz), 
and broadband (remaining signal > 2 MHz) components were extracted for each acquisition. 
The power and cumulative energy in these frequency subsets were calculated for each 
acquisition over the entire exposure time. In order to characterise the spectrum of the 
sonoluminescence, the signal of the filtered PMT was normalised with the total amount of light 
generated (Figure S1). This enabled a comparison between experimental runs. Each experiment 
was repeated n = 3 times. The fluorescence and absorbance readings were also performed four 
times for each sample. The average and the standard deviation within each group are presented. 
RESULTS AND DISCUSSION 
 Measurements of sonoluminescence and acoustic emissions at 23°C were made for 
microbubbles manufactured in-house 28 with a sulphur hexafluoride (SF6) or oxygen (O2) gas 
cores and the commercially available contrast agent Sonovue® (Figure S1), While all 
microbubbles tested produced sonoluminescence when exposed to US (Figure 2), reduced 
sonoluminescence counts were observed for O2 microbubbles compared to Sonovue
® and SF6 
microbubbles. This was attributed to the lower stability of O2 microbubbles and the higher 
solubility of O2 in aqueous solutions compared to SF6. The reduced broadband energy levels 
produced by O2 microbubbles (Figure 2) further confirmed these results. The pulse height 
distribution of individual sonoluminescence events was however found to be comparable 
between the formulations (Figure S2) highlighting that the cavitation of these systems 
generated comparable collapse conditions and sonoluminescence 10,32. 
 
Figure 2. Sonoluminescence and broadband acoustic emissions produced by phospholipid-
coated microbubbles driven at 1 MHz with an intensity of 3.5 W/cm2, 30% duty cycle, and 100 
Hz pulse repetition frequency for 2 minutes. The total PMT (photomultiplier tube) counts 
above 6 mV in amplitude and broadband energy of acoustic emissions for three microbubble 
formulations and a water control are displayed. (n=3 runs of 1000 acquisitions each, error bars 
indicate standard deviations).  
 
The spectrum of the light generated using SF6 microbubbles was measured using a set of five 
optical filters at room temperature. Figure 3 shows a broad spectrum with an increased 
sonoluminescence generation at the lower wavelengths. As the intensity of sonoluminescence 
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reported here was low, the use of a monochromator to obtain a higher wavelength resolution 
was not feasible, thus specific molecular features in the optical spectrum were not discernible. 
However, sonoluminescence in water has been reported at 1 MHz with a broad continuous 
spectrum and no molecular features.12,33,34 Such broad spectra have been associated with 
radiation emissions from cavitation events e.g. blackbody9, bremsstrahlung35,36, and/or 
recombination radiations37,38. Although, no consensus has been reached on the exact 
mechanisms, the generation of reactive oxygen species (ROS) during microbubble cavitation 
such as hydrogen peroxide39 and hydroxyl radical40,41 concurs with the recombination radiation 
theory12,38.  
 
 
Figure 3. Spectrum of sonoluminescence for diluted SF6 microbubbles at 23°C. The percentage 
of overall sonoluminescence reflects the normalised counts from the filtered PMT at specific 
wavelengths over 1000 acquisitions with the counts from a non-filtered PMT. The normalised 
count was then corrected for the bandwidth of the optical filters used and the PMT sensitivity 
at that wavelength. n = 3 runs were performed for each wavelength and error bars indicate the 
standard deviation between the runs. 
 
An increase in bulk solution temperature has been reported to affect sonoluminescence by: (1) 
increasing the number of sonoluminescence events due to an increase in the number of 
cavitation events 10, and (2) lowering the amplitude of individual sonoluminescence events due 
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to lowering of the intensity of collapse 32. Measurements were taken at 10, 23, and 37° and 
their comparison in Figure 4a shows the expected increase in sonoluminescence occurrence 
and broadband activity at 37°C when SF6 microbubbles were used as cavitation nuclei. As the 
amplitude of sonoluminescence was examined (Figure 4b), a decrease in the number of high 
amplitude sonoluminescence events (> 60 mV) was observed with higher bulk solution 
temperatures (Figure 4b inset). Thus, these results demonstrate that at biologically relevant 
temperatures, a greater number of sonoluminescence events occur when microbubbles are 
exposed to mild therapeutic US conditions, however the amplitude of individual 
sonoluminescence events is reduced. 
 
The generation of sonoluminescence by microbubbles and ultrasound is potentially of great 
importance for the fields of  both photo- and sonodynamic therapy (PDT and SDT 
respectively). In PDT, significant efforts have been made to design sensitisers with increased 
absorption at wavelengths that allow improved penetration of light in tissue. Although the 
therapeutic effects of SDT have been reported since 1989 17, the explanation behind the 
activation of the sensitiser with this method was not well accepted. Therefore, we measured 
the sonoluminescence output with and without the presence of an absorbing sensitiser, in this 
case Rose Bengal (RB). Figure 5a highlights that the presence of RB and SF6 microbubbles at 
37°C led to a decrease in sonoluminescence measured at the absorption wavelength of the drug 
(560 nm, Figure S3) compared to a reference wavelength (350 nm). Hence, sonoluminescence 
from cavitating microbubbles can be absorbed by surrounding sensitisers, leading to their 
activation. These results support the hypothesis that sonoluminescence and the resulting 
transfer of energy to an accepting sensitiser is a key mechanism underlying SDT and are 
consistent with reports by Umemura et al. 15 and Giuntini et al. 14 at room temperatures and 
without the use of exogenously-added cavitation nuclei. Additionally, Figure 5b shows that at 
the same ultrasound parameters, the combination of RB and SF6 microbubbles in solution 
produced significantly more singlet oxygen radicals compared to microbubbles alone, 
confirming the activation of RB.  
 
 Figure 4. Sonoluminescence and broadband acoustic emissions from SF6 microbubbles diluted 
in deionised water at 10, 23, 37°C (n=3, error bars indicate standard deviations for each run). 
a, Total PMT counts above 6 mV in amplitude and broadband energy for three different 
temperatures are displayed. b, Number of PMT counts for increasing peak amplitude. Number 
of PMT counts in each bin is normalised by the total number of counts recorded in each run. 
The inset shows the sum of normalised PMT counts above 60 mV for each temperature tested. 
These results indicate that with increasing temperatures, while the number of cavitation events 
increases, their amplitude decreases. The sample temperature before and after ultrasound 
exposure did not fluctuate substantially (±1°C). 
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Figure 5. The addition of Rose Bengal (RB) to SF6 microbubbles (SF6MB), and the resulting 
effect on sonoluminescence, broadband emissions and singlet oxygen radical generation. a, 
Percent of overall sonoluminescence measured with optical filters for 560 nm and 350 nm. 
Filtered PMT signal was normalised by the overall counts recorded by the non-filtered 
reference PMT and for the bandwidth of the filter used. These were acquired for water, SF6 
microbubbles (SF6MB), SF6 microbubbles and Rose Bengal samples at 37°C (n = 3 runs, each 
of 1000 acquisitions). Rose Bengal peak absorbance is known to be at 559 nm (Figure S3). 
The sonoluminescence measurement at 560 nm was made to assess the absorption of 
sonoluminescence by the sensitiser and compared to 350 nm for reference. b, The activation of 
Rose Bengal was assessed through the generation of cytotoxic singlet oxygen radical. This was 
characterised by ab increase in the fluorescence intensity of Singlet Oxygen Sensor Green 
(SOSG, left axis). The different groups were exposed to 1 MHz, 462 mVpk-pk, 30% duty cycles, 
100 Hz pulse repetition frequency for 30 seconds (n = 3). The ultraharmonic emissions of 
microbubbles were captured using a passive acoustic detector and displayed as the overall 
ultraharmonic energy during the exposure (right axis). 
 
In contrast, the presence of reactive oxygen species did not affect the activity of Rose Bengal 
at ambient temperatures and pressures (Figure S4) indicating that pyrolysis-induced ROS 
generation are not involved in the activation of Rose Bengal. Further, microbubble cavitation 
did not lead to significant degradation of Rose Bengal demonstrating that significant pyrolysis 
of the sensitiser itself does not occur at these exposure conditions (Figure S5). 
 
There are several aspects of these results that may be important for both diagnostic and 
therapeutic applications of ultrasound and microbubbles. In the absence of cavitation, 
ultrasound is a non-ionising modality and epidemiological studies of ultrasound imaging have 
not identified any significant health hazards associated with the technique 42,43. Yet, bubble 
cavitation was shown to cause ionisation of molecules as seen with a broad continuum of 
sonoluminescence, and the production of excited species and radicals 36,38. Here we 
demonstrate that, in the presence of microbubbles, cavitation produces reactive oxygen species 
and sonoluminescence. The sonoluminescence measured in this study is unlikely to cause 
phototoxicity as the number of photons is below that associated with the safe use of lasers in 
medical applications 44,45. In contrast, the generation of free radicals could cause local 
cytotoxicity; although the short lifetimes of radicals 46 and the small reaction volume 1 of 
cavitation will restrict the region of damage, making such an approach ideal for targeted 
applications in oncology.  
 
CONCLUSIONS 
In summary, cavitation of microbubbles under mild therapeutic ultrasound conditions was 
found to generate sonoluminescence, the intensity of which was positively correlated with the 
broadband energy of microbubble acoustic emissions. Further, this work confirms that 
sonoluminescence is involved in the activation of photosensitisers which allows a greater 
production of reactive oxygen species during SDT. The sensitisers used for PDT can then be 
locally activated by energy transfer through the sonoluminescence generated by ultrasound and 
microbubbles enabling the treatment of a wider range of lesions using SDT. 
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